What Is Egrifta? (Tesamorelin for HIV Lipodystrophy)

Fewer than 15% of FDA-approved peptide therapies target body composition directly through growth hormone pathways. And Egrifta is one of them. Approved in 2010, Egrifta (tesamorelin) remains the only FDA-approved treatment specifically indicated for reducing excess abdominal fat in HIV patients with lipodystrophy, a metabolic complication that affects up to 40% of people on long-term antiretroviral therapy. This isn't cosmetic fat reduction. Visceral adipose tissue in HIV lipodystrophy drives insulin resistance, dyslipidemia, and cardiovascular risk independent of total body weight.

We've worked extensively with peptide mechanisms across metabolic research applications. The gap between how Egrifta is marketed and how its biological pathway actually works matters. Because tesamorelin doesn't burn fat directly, and the metabolic changes it produces require continuous administration to maintain.

What is Egrifta and how does it work in the body?

Egrifta is the brand name for tesamorelin, a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone (GH) secretion from the anterior pituitary. Unlike exogenous GH therapy, which directly introduces growth hormone into circulation, tesamorelin preserves the body's natural pulsatile GH release pattern while amplifying peak amplitude. This distinction matters. Pulsatile GH secretion maintains physiological feedback regulation through IGF-1, reducing the risk of supraphysiological GH exposure and associated adverse metabolic effects like hyperglycemia.

The misconception most clinical summaries skip: Egrifta doesn't target adipocytes directly. Growth hormone released in response to tesamorelin acts on hepatic GH receptors to stimulate IGF-1 production, which then drives lipolysis in visceral adipose tissue through mechanisms including increased hormone-sensitive lipase activity and reduced lipogenesis. Visceral fat is more responsive to GH-mediated lipolysis than subcutaneous fat because visceral adipocytes express higher densities of beta-adrenergic receptors and lower alpha-2 adrenergic receptor density. The receptor profile that determines lipolytic sensitivity.

This article covers the exact mechanism through which tesamorelin reduces visceral adipose tissue, the clinical trial data that defined its FDA approval, how dosing and administration work in practice, what happens when treatment stops, and what the research community has learned about tesamorelin applications beyond HIV lipodystrophy. Including its investigation in NAFLD and cognitive function.

The Biology Behind Egrifta: Growth Hormone Pathways and Visceral Fat

Tesamorelin is a 44-amino-acid peptide sequence identical to the first 29 amino acids of endogenous human GHRH, with a 15-amino-acid extension that increases half-life and receptor binding affinity. This molecular design allows tesamorelin to bind selectively to GHRH receptors on somatotroph cells in the anterior pituitary, triggering a signaling cascade that culminates in growth hormone synthesis and secretion. Peak GH levels occur approximately 30 minutes post-injection, with a return to baseline within 2–4 hours. Preserving the physiological pulsatility that endogenous GHRH normally provides.

Growth hormone released in response to tesamorelin binds to GH receptors throughout the body, but the metabolic effects relevant to lipodystrophy occur primarily in the liver and adipose tissue. In hepatocytes, GH receptor activation stimulates IGF-1 production via the JAK2-STAT5 signaling pathway. IGF-1 levels rise within hours of tesamorelin administration and remain elevated for 12–24 hours, creating a window of metabolic activity that extends beyond the brief GH pulse. IGF-1 then mediates the lipolytic effect: it activates hormone-sensitive lipase (HSL) in adipocytes, the rate-limiting enzyme that hydrolyzes stored triglycerides into free fatty acids and glycerol for oxidation or export.

Visceral adipose tissue responds more aggressively to GH-IGF-1 signaling than subcutaneous fat for several reasons. Visceral adipocytes exhibit higher beta-adrenergic receptor density, lower alpha-2 adrenergic receptor expression (which inhibits lipolysis), and greater sensitivity to catecholamines released downstream of GH. This receptor profile makes visceral fat preferentially responsive to lipolytic stimuli. Which is why tesamorelin produces selective reductions in abdominal visceral adipose tissue (VAT) without proportional loss of subcutaneous fat or lean mass. The TRIM trial, published in The Lancet in 2010, demonstrated mean VAT reductions of 15.2% at 26 weeks in HIV patients receiving 2mg daily tesamorelin versus 4.4% placebo. A statistically significant and clinically meaningful difference.

One mechanism detail most summaries omit: tesamorelin does not suppress appetite or alter caloric intake. Weight loss observed in trials averaged 1–2 kg over 26 weeks. Modest compared to the dramatic VAT reductions measured by CT imaging. This disconnect confirms that tesamorelin's effect is redistribution and mobilization of visceral fat stores, not generalized caloric deficit. Patients maintained stable lean mass and subcutaneous fat while losing visceral adiposity. A body composition shift that GLP-1 agonists and caloric restriction alone do not consistently produce.

Critical regulatory context: Egrifta carries a black-box warning related to glucose metabolism. GH is a counter-regulatory hormone that opposes insulin action. It promotes hepatic gluconeogenesis and reduces peripheral glucose uptake. Approximately 5–7% of patients in pivotal trials developed new-onset diabetes or worsening glycemic control, and baseline HbA1c >7.0% was an exclusion criterion in the original TRIM study. Patients with pre-existing diabetes require close monitoring if prescribed tesamorelin, and those with poorly controlled hyperglycemia are contraindicated.

HIV Lipodystrophy: The Clinical Problem Egrifta Was Designed to Solve

HIV-associated lipodystrophy is a metabolic syndrome characterized by abnormal fat distribution, insulin resistance, dyslipidemia, and increased cardiovascular risk. It emerged as a recognized complication in the late 1990s following the widespread adoption of highly active antiretroviral therapy (HAART), particularly regimens containing thymidine analogue nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine and zidovudine, and first-generation protease inhibitors. The pathophysiology is multifactorial: mitochondrial toxicity from NRTIs disrupts adipocyte differentiation and lipid metabolism, while protease inhibitors interfere with SREBP-1 and PPAR-gamma pathways critical to adipogenesis.

Lipodystrophy manifests in two primary patterns: lipoatrophy (fat loss in the face, limbs, and buttocks) and lipohypertrophy (fat accumulation in the abdomen, dorsocervical region, and breasts). Many patients exhibit mixed presentations. Visceral adipose tissue accumulation is particularly problematic because VAT is metabolically active. It secretes pro-inflammatory adipokines including TNF-alpha, IL-6, and resistin, which drive systemic insulin resistance, hepatic steatosis, and atherogenic dyslipidemia. Studies in HIV-positive cohorts have shown that excess VAT correlates independently with coronary artery disease risk, even after adjusting for BMI and traditional cardiovascular risk factors.

The prevalence of lipodystrophy in HIV populations varies by antiretroviral regimen and duration of therapy. Older estimates placed prevalence at 40–50% in patients on long-term HAART, though modern integrase inhibitor-based regimens produce lower rates of metabolic disruption. Nonetheless, a substantial cohort of long-term HIV survivors continues to live with lipodystrophy developed during earlier treatment eras. And for this group, Egrifta represents the only FDA-approved pharmacological option specifically targeting visceral fat accumulation.

Before tesamorelin, management strategies were limited to antiretroviral regimen switching (which rarely reversed established lipodystrophy), metformin for insulin resistance, and statins for dyslipidemia. None of which directly addressed VAT. Surgical options like liposuction remove subcutaneous fat but cannot access visceral depots. Tesamorelin filled a therapeutic gap by offering a mechanism-based approach to VAT reduction without requiring changes to effective antiretroviral therapy.

In our experience reviewing peptide research across metabolic conditions, tesamorelin remains one of the few examples where a peptide therapy received FDA approval for a body composition indication rather than a disease endpoint like diabetes or obesity. The regulatory pathway was anchored to CT-measured VAT reduction as a surrogate marker, not weight loss or cardiovascular outcomes. A distinction that shaped both the approval language and the clinical use case.

Egrifta Dosing, Administration, and What to Expect During Treatment

Egrifta is supplied as a lyophilised powder in single-dose vials containing 2mg tesamorelin (as the acetate salt). Reconstitution requires 2.2mL of supplied sterile water for injection, producing a solution intended for subcutaneous injection into the abdomen. The standard adult dose is 2mg administered once daily, preferably at bedtime to align with the body's natural nocturnal GH secretion peak. Though the clinical significance of injection timing has not been rigorously tested in head-to-head trials.

Administration technique mirrors other subcutaneous peptide protocols: rotate injection sites within the abdominal region to reduce lipohypertrophy risk, use proper aseptic technique, and avoid injecting into areas with visible lipodystrophy or scarring. Once reconstituted, Egrifta must be used immediately. The sterile water formulation does not contain bacteriostatic agents, so multi-dose use from a single vial is not supported. This differs from compounded peptides reconstituted with bacteriostatic water, which allow refrigerated storage for up to 28 days.

Patients typically undergo baseline CT or MRI imaging to quantify visceral adipose tissue area at the L4–L5 vertebral level before initiating therapy. Follow-up imaging at 26 weeks assesses treatment response, defined as a reduction in VAT area of at least 10–15% from baseline. Not all patients respond equally. Approximately 60–70% of treated patients in the pivotal TRIM trial achieved clinically meaningful VAT reductions, while 30–40% demonstrated minimal or no response. Predictors of non-response are not well-characterized, though baseline VAT area, insulin resistance severity, and concurrent metabolic medications may play roles.

Adverse events reported in clinical trials include injection-site reactions (erythema, pruritus, induration) in up to 30% of patients, arthralgias and myalgias in 15–20%, and peripheral edema in approximately 10%. These effects are generally mild and transient, resolving within the first 8–12 weeks of therapy. The more concerning adverse event profile relates to glucose metabolism: as noted earlier, 5–7% of patients developed new-onset impaired glucose tolerance or diabetes. Monthly fasting glucose and HbA1c monitoring is recommended during the first six months of treatment.

Here's the honest answer about treatment duration: Egrifta is not a short-term intervention. VAT reductions observed during the first 26 weeks are maintained only with continuous daily administration. The TRIM extension study demonstrated that patients who discontinued tesamorelin after 26 weeks experienced VAT rebound to near-baseline levels within 26 weeks of stopping. Confirming that the metabolic effect is treatment-dependent, not a permanent reset of fat distribution. For patients who achieve meaningful VAT reduction and wish to maintain it, indefinite daily injections are required.

Cost represents a significant barrier. The wholesale acquisition cost for Egrifta exceeds $4,500 per month, and insurance coverage is inconsistent. Many payers classify it as a specialty medication requiring prior authorization, step therapy, or documentation of CT-confirmed excess VAT. Patients without insurance or adequate coverage may find the out-of-pocket cost prohibitive, particularly given the indefinite treatment duration required.

Egrifta Clinical Trial Data: What the Evidence Actually Shows

The FDA approval of Egrifta was based primarily on two Phase 3 randomized, double-blind, placebo-controlled trials: TRIM (Tesamorelin in the Reduction of Truncal Obesity in HIV) and the subsequent 26-week extension study. The TRIM trial enrolled 412 HIV-positive adults with excess abdominal fat (VAT area ≥130 cm² by CT) and stable antiretroviral therapy. Participants were randomized 2:1 to receive tesamorelin 2mg daily or placebo for 26 weeks.

Primary endpoint results: tesamorelin-treated patients demonstrated a mean reduction in VAT of −15.2% (−17.0 cm²) compared to −4.4% (−4.8 cm²) in placebo (p<0.0001). This represented an absolute difference of approximately 12 cm². Roughly 10% of baseline VAT area. Subcutaneous adipose tissue (SAT) did not change significantly in either group, confirming selectivity for visceral depots. Body weight declined modestly (−1.0 kg tesamorelin vs +0.2 kg placebo), consistent with the preferential loss of metabolically dense visceral fat rather than generalized weight reduction.

Secondary metabolic endpoints showed mixed results. Triglyceride levels decreased by approximately 15–20% in tesamorelin-treated patients, a favorable lipid effect consistent with reduced hepatic fat delivery from visceral adipose stores. However, fasting glucose increased slightly in the tesamorelin group (+3–5 mg/dL on average), and HbA1c showed a non-significant upward trend. IGF-1 levels increased predictably, rising by 50–80% above baseline in tesamorelin recipients. Expected pharmacodynamic evidence of GHRH receptor engagement and intact GH secretion.

The extension phase allowed patients to continue or discontinue treatment for an additional 26 weeks. Patients who remained on tesamorelin maintained their VAT reductions (−16.8% from original baseline at week 52), while those who stopped experienced VAT rebound to within 5 cm² of baseline by week 52. Confirming that the effect is reversible and requires continuous therapy.

Critical limitation: neither TRIM nor its extension were powered to detect differences in cardiovascular outcomes, diabetes incidence, or mortality. The trials used VAT area as a surrogate endpoint under the assumption that reducing visceral fat would translate to improved cardiometabolic health. An assumption supported by observational data linking VAT to insulin resistance and cardiovascular risk, but not proven in a tesamorelin-specific outcomes trial. The FDA approval was granted based on body composition changes, not hard clinical endpoints.

A subsequent Phase 3 trial investigated tesamorelin in non-alcoholic fatty liver disease (NAFLD) among HIV-negative patients, based on mechanistic rationale that GH-mediated lipolysis might reduce hepatic steatosis. The trial met its primary endpoint of liver fat reduction measured by MRI, but did not lead to a second FDA indication. Likely because NAFLD treatment guidelines prioritize histological endpoints (NASH resolution, fibrosis regression) over imaging-based fat quantification, and tesamorelin's glucose-raising effects posed concerns in a population already at high risk for diabetes.

Egrifta vs Other Peptides: Comparison Table

Tesamorelin occupies a unique regulatory and mechanistic niche. The table below compares Egrifta to other peptides investigated or approved for metabolic applications, clarifying where tesamorelin fits in the broader landscape.

| Peptide | Primary Mechanism | FDA Approval Status | Target Population | Typical Dose | Key Metabolic Effect | Professional Assessment |
|—|—|—|—|—|—|
| Tesamorelin (Egrifta) | GHRH agonist. Stimulates endogenous GH secretion | FDA-approved (2010) for HIV lipodystrophy | HIV patients with excess visceral fat | 2mg SC daily | Selective VAT reduction; modest triglyceride lowering; no appetite suppression | Only FDA-approved peptide for body composition in HIV; requires continuous use; glucose monitoring mandatory |
| Semaglutide (Wegovy) | GLP-1 receptor agonist. Delays gastric emptying, reduces appetite | FDA-approved for obesity (2021) | Adults with BMI ≥30 or ≥27 + comorbidity | 2.4mg SC weekly | Mean 15% body weight reduction; mixed fat loss (VAT + SAT + lean mass) | Superior total weight loss; broader indication; appetite-driven mechanism limits adherence in some |
| Tirzepatide (Mounjaro, Zepbound) | Dual GIP/GLP-1 agonist | FDA-approved for obesity (2023) | Adults with BMI ≥30 or ≥27 + comorbidity | 5–15mg SC weekly | Mean 20% body weight reduction at 15mg; improves insulin sensitivity | Strongest weight-loss efficacy; similar GI side-effect profile as semaglutide; no selective VAT effect |
| Sermorelin | GHRH agonist (shorter peptide sequence) | Not FDA-approved (research/compounding only) | Off-label for aging, body composition | 200–500mcg SC daily | Modest GH elevation; inconsistent body composition data | Shorter half-life than tesamorelin; less robust clinical evidence; compounded formulations unregulated |
| CJC-1295 | GHRH agonist with extended half-life | Not FDA-approved (research only) | Research applications only | Varies (typically 1–2mg SC weekly) | Sustained GH elevation; limited published human data | Longer half-life reduces injection frequency; lacks Phase 3 trial data; regulatory status unclear |
| Ipamorelin | Growth hormone secretagogue (ghrelin mimetic) | Not FDA-approved (research only) | Research applications only | 200–300mcg SC 2–3x daily | Stimulates GH pulse; minimal impact on cortisol or prolactin | Ghrelin pathway differs from GHRH; no published metabolic outcome trials; used in research stacks |

Bottom Line: Tesamorelin is the only GHRH agonist with FDA approval and robust Phase 3 data for a metabolic indication. GLP-1 agonists produce greater total weight loss but lack selectivity for visceral fat. Other GHRH peptides (sermorelin, CJC-1295) lack regulatory approval and comparable clinical validation.

What If: Egrifta Scenarios

What If I'm HIV-Positive with Abdominal Fat Gain But My Doctor Hasn't Mentioned Egrifta?

Ask your provider whether your abdominal fat distribution qualifies as lipodystrophy and whether baseline CT imaging to quantify visceral adipose tissue would be appropriate. Many HIV specialists reserve Egrifta for patients with documented excess VAT (typically ≥130 cm² at L4–L5 on CT) rather than subjective clinical assessment alone, because the metabolic and cardiovascular risks correlate with visceral depot size, not total body weight or waist circumference. If your provider is unfamiliar with Egrifta, request referral to an HIV metabolic specialist or endocrinologist experienced in lipodystrophy management. Tesamorelin prescribing requires familiarity with growth hormone physiology, glucose monitoring protocols, and realistic outcome expectations.

What If I Start Egrifta and My Blood Sugar Increases — Should I Stop?

Contact your prescriber immediately for glucose monitoring and risk-benefit reassessment, but do not discontinue without guidance. Growth hormone is a counter-regulatory hormone that opposes insulin, so modest glucose elevations (5–10 mg/dL fasting glucose increase) are common and expected. If HbA1c remains below 6.5% and fasting glucose stays under 110 mg/dL, continuation with monthly monitoring is often appropriate. However, if you develop fasting glucose consistently above 126 mg/dL or HbA1c above 6.5%, your provider may recommend discontinuation or initiation of metformin to manage emerging insulin resistance. The FDA black-box warning exists because uncontrolled hyperglycemia poses greater long-term risk than the cardiovascular benefit of VAT reduction. Each case requires individualized risk stratification.

What If I Achieve My Target VAT Reduction — Can I Stop Egrifta and Keep the Results?

No. VAT rebound occurs predictably within 6–12 months of stopping tesamorelin. The TRIM extension data showed near-complete reversal of VAT reduction when patients discontinued after 26 weeks, confirming that tesamorelin's metabolic effect is active treatment-dependent, not a durable reset of adipocyte metabolism or fat partitioning. If you wish to maintain reduced visceral fat, indefinite daily administration is required. Some patients and providers explore maintenance strategies like reduced dosing frequency (every other day) or intermittent treatment cycles, but no controlled trial data support these approaches. They represent off-label experimentation.

What If I'm Not HIV-Positive But Have Excess Visceral Fat — Can I Get Egrifta Prescribed Off-Label?

Technically yes, though insurance coverage will almost certainly be denied, and cost becomes prohibitive at $4,500+ per month out-of-pocket. Off-label prescribing of tesamorelin for general visceral obesity or metabolic syndrome occurs occasionally in concierge or anti-aging practices, but it lacks evidence-based support. The Phase 3 NAFLD trial in non-HIV patients showed liver fat reduction but did not result in FDA approval, and no trials have evaluated cardiovascular outcomes in general populations. GLP-1 receptor agonists (semaglutide, tirzepatide) produce superior total weight loss with weekly dosing and broader insurance coverage for obesity indications, making them more practical first-line options for non-HIV patients seeking metabolic improvement.

The Clinical Truth About Egrifta

Let's be direct: Egrifta is not a breakthrough obesity drug, and it's not a viable weight-loss option for the general population. It's a narrowly indicated therapy for a specific metabolic complication affecting a subset of people living with HIV. And even within that population, it works for only 60–70% of treated patients, requires daily injections indefinitely, costs more than $50,000 annually, and carries a black-box warning for glucose metabolism disruption.

The mechanism is elegant: by amplifying the body's natural growth hormone pulses rather than bypassing them with exogenous GH, tesamorelin reduces some of the metabolic risks associated with supraphysiological GH exposure. But elegance doesn't translate to universal applicability. The selectivity for visceral fat is real. CT data from TRIM unambiguously demonstrate preferential VAT loss. But the magnitude is modest (15% reduction), the effect is reversible upon stopping, and the clinical outcome data (cardiovascular events, diabetes prevention, mortality) simply don't exist. The FDA approved Egrifta based on a surrogate imaging endpoint, not hard outcomes.

For the population it was designed to treat. HIV-positive individuals with antiretroviral-induced lipodystrophy, documented excess VAT on imaging, and adequate glucose control. Egrifta represents the only FDA-approved pharmacological tool that directly targets the problem. It's not a perfect solution, but it's the best available option when lifestyle modification and regimen switching have failed. For everyone else, the cost-benefit calculation doesn't hold. GLP-1 agonists deliver more weight loss, broader metabolic benefits, and better insurance coverage. Even if they don't selectively spare subcutaneous fat.

The research community continues to explore tesamorelin's potential beyond HIV lipodystrophy, particularly in NAFLD/NASH and neurocognitive applications (based on preclinical data suggesting GH-IGF-1 neuroprotective effects). Those investigations may eventually expand the evidence base, but as of 2026, the approved indication remains unchanged.

Understanding Tesamorelin in the Broader Peptide Research Context

For researchers investigating growth hormone pathways, body composition modulators, or metabolic peptides, tesamorelin provides a validated proof-of-concept: GHRH receptor agonism can produce measurable, selective changes in visceral adiposity without exogenous GH administration. This mechanistic pathway has informed broader peptide research into aging, sarcopenia, and metabolic syndrome. Domains where endogenous GH secretion declines with age and contributes to unfavorable body composition shifts.

Our work at Real Peptides emphasizes the importance of understanding not just what a peptide does, but how it achieves that effect and under what conditions those effects are maintained. Tesamorelin's requirement for continuous daily dosing to sustain VAT reduction illustrates a broader principle in peptide pharmacology: many metabolic peptides modulate active physiological processes rather than inducing permanent state changes. When the peptide is withdrawn, the underlying physiology returns. Unless the intervention period allowed for durable adaptation (weight loss-induced improvements in insulin sensitivity, for example, which can persist if weight is maintained).

Researchers exploring related peptides like Tesamorelin Ipamorelin Growth Hormone Stack or standalone Tesamorelin Peptide formulations should note that while tesamorelin is FDA-approved for therapeutic use, research-grade peptides are intended for investigational applications only. Not for human consumption outside of clinical trials or prescribed medical treatment. The distinction between pharmaceutical-grade Egrifta (manufactured under FDA cGMP oversight by EMD Serono) and research-grade tesamorelin (synthesized for laboratory investigation) is regulatory and quality-assurance infrastructure, not molecular identity.

For labs investigating growth hormone secretagogues more broadly, our catalog includes related compounds such as Sermorelin, Ipamorelin, and CJC1295 Ipamorelin 5MG 5MG stacks. Each representing distinct receptor targets and pharmacokinetic profiles within the growth hormone axis. Comparative studies examining receptor selectivity, pulse amplitude, and downstream metabolic effects require high-purity reference compounds with verified amino acid sequencing. Which is why our small-batch synthesis protocol prioritizes sequence fidelity and third-party verification. You can explore our full range of research-grade peptides and growth hormone modulators in our complete peptide collection.

The broader lesson from Egrifta's development and approval: niche indications with well-defined patient populations and measurable surrogate endpoints (CT-quantified VAT in this case) can support regulatory pathways for peptides that wouldn't meet approval thresholds for broader obesity or metabolic syndrome indications. This regulatory model may inform future peptide development strategies, particularly as imaging biomarkers and metabolic phenotyping become more standardized in clinical trials.

For research institutions working on metabolic peptides, understanding what made tesamorelin successful. A defined mechanism, a specific unmet need, robust Phase 3 data, and a quantifiable imaging endpoint. Provides a template. The same rigor that brought Egrifta to approval in 2010 remains the standard for any investigational peptide aiming for clinical translation. Whether investigating lipodystrophy, NAFLD, sarcopenia, or other metabolic conditions, the pathway from bench to bedside requires not just pharmacological activity, but reproducible, clinically meaningful outcomes measured with precision. If your work intersects with any of these domains and you need reliably sequenced, high-purity peptides, visit Real Peptides to review our synthesis standards and request certificates of analysis.

Egrifta was never intended to be a mass-market solution. It was designed to solve a specific, clinically significant problem for a defined patient group. Fifteen years post-approval, that original mission remains both its strength and its limitation.